2084-13-1

Usage

InChI:InChI=1/C9H8O4/c10-8(11)5-6-2-1-3-7(4-6)9(12)13/h1-4H,5H2,(H,10,11)(H,12,13)

Upstream product

• 111-65-9 octane 
• 1822-71-5 n-pentylsodium 
• 108-88-3 toluene 
• 201230-82-2 carbon monoxide 
• 28188-41-2 m-(bromomethyl)benzonitrile 
• 124-38-9 carbon dioxide 
• 101-97-3 Ethyl 2-phenylethanoate 
• 5689-33-8 ethyl 3-cyanomethylbenzoate 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 68432-92-8 methyl 3-cyanomethylbenzoate 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 1878-67-7 3-Bromophenylacetic acid 
• 52798-00-2 (3-cyano-phenyl)-acetic acid methyl ester 
• 14194-05-9 ethyl 2-(3-acetylphenyl)acetate 

Downstream Products

• 107150-74-3 3-ethoxycarbonylphenylacetic acid ethyl ester 
• 90612-85-4 (3-carboxy-cyclohexyl)-acetic acid 
• 6553-10-2 (+/-)-(cis-3-carboxy-cyclohexyl)-acetic acid 
• 121-91-5 isophthalic acid 
• 6553-12-4 bicyclo[3.2.1]octan-6-one 
• 105904-83-4 (3-dimethylaminomethyl-phenethyl)-dimethyl-amine 
• 1278403-36-3 C₂₀H₂₁NO₄ 
• 1416319-77-1 meta-Ar-CDM-COCl 
• 1416319-76-0 meta-Ar-CDM-CO₂H 
• 1429653-88-2 methyl 3-(2-((2-((tert-butyldimethylsilyl)oxy)ethyl)(phenyl)amino)-2-oxoethyl)benzoate 
• 1446499-66-6 3-(2-((2-((tert-butyldimethylsilyl)oxy)ethyl)(phenyl)amino)-2-oxoethyl)-N-hydroxybenzamide 
• 1429652-59-4 N-hydroxy-3-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl) benzamide 
• 113496-14-3 methyl 3-carboxyphenyl acetate 
• 509093-57-6 3-methanesulfonyl-N-(1-(2-morpholin-4-yl-ethyl)-1H-benzoimidazol-2-yl)-benzamide 

Relevant academic research and scientific papers

Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof

The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE 1

The compounds of the present invention are HDAC6 selective inhibitors which are identified on the basis of accumulation of acetylated tubulin without accumulation of acetylated histones. Histone deacetylase or "HDAC" refers to enzymes capable of cleaving an acetyl group (-C(=0)CH3) from proteins, including histone and microtubulins. Compositions comprising the molecules and methods for their use to inhibit the activity of histone deacetylase, including for treatment, are also disclosed.

DISUBSTITUTED MALEIC ANHYDRIDES WITH ALTERED KINETICS OF RING CLOSURE

We describe anhydride compounds suitable for physiologically labile modification of amine- containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

EP2 RECEPTOR AGONISTS

A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).

CATALYTIC PHASE TRANSFER CARBONYLATION OF BENZYL HALIDES WITH IRON PENTACARBONYL.

Benzyl halides are readily carbonylated to arylacetic acids in a two-phase system (aqueous sodium hydroxide (1M), tetrabutylammonium sulfate ; organic phase (CH2Cl2 or C6H6 or C6H5CH3)), using a catalytic amount of the cheap, easy to handle iron pentacarbonyl under carbon monoxide atmosphere.